75 related articles for article (PubMed ID: 19654575)
1. Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial.
Murtola TJ; Tammela TL; Määttänen L; Ala-Opas M; Stenman UH; Auvinen A
Br J Cancer; 2009 Sep; 101(5):843-8. PubMed ID: 19654575
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Finasteride and Dutasteride on Risk of Prostate Cancer in Patients with Benign Prostatic Hyperplasia: A Pooled Analysis of 15 Real-world Databases.
Yang DY; Seo WW; Park RW; Rhee SY; Cha JM; Hah YS; Jeong CW; Kim KJ; Yang HJ; Kim DK; Ha JY
World J Mens Health; 2024 May; ():. PubMed ID: 38772542
[TBL] [Abstract][Full Text] [Related]
3. Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
Neuhouser ML; Till C; Kristal A; Goodman P; Hoque A; Platz EA; Hsing AW; Albanes D; Parnes HL; Pollak M
Cancer Prev Res (Phila); 2010 Mar; 3(3):279-89. PubMed ID: 20179296
[TBL] [Abstract][Full Text] [Related]
4. Serum lycopene concentration and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
Kristal AR; Till C; Platz EA; Song X; King IB; Neuhouser ML; Ambrosone CB; Thompson IM
Cancer Epidemiol Biomarkers Prev; 2011 Apr; 20(4):638-46. PubMed ID: 21335507
[TBL] [Abstract][Full Text] [Related]
5. More on Long-Term Effects of Finasteride on Prostate Cancer Mortality.
Garnick MB
N Engl J Med; 2019 May; 380(20):e38. PubMed ID: 31091399
[No Abstract] [Full Text] [Related]
6. More on Long-Term Effects of Finasteride on Prostate Cancer Mortality.
Stapff MP; Palm S
N Engl J Med; 2019 May; 380(20):e38. PubMed ID: 31091398
[No Abstract] [Full Text] [Related]
7. More on Long-Term Effects of Finasteride on Prostate Cancer Mortality. Reply.
Goodman PJ; Tangen CM; Thompson IM
N Engl J Med; 2019 May; 380(20):e38. PubMed ID: 31091400
[No Abstract] [Full Text] [Related]
8. Finasteride and prostate cancer.
Khan MA; Partin AW
Rev Urol; 2004; 6(2):97-8. PubMed ID: 16985587
[No Abstract] [Full Text] [Related]
9. The Crosstalk between Nerves and Cancer-A Poorly Understood Phenomenon and New Possibilities.
Benzaquen D; Lawrence YR; Taussky D; Zwahlen D; Oehler C; Champion A
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791953
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial evaluating the effect of low-dose chlormadinone in patients with low-risk prostate cancer: PROSAS study.
Sugimoto M; Kakehi Y; Horie S; Hirao Y; Akaza H
Jpn J Clin Oncol; 2022 Feb; 52(2):187-196. PubMed ID: 34698353
[TBL] [Abstract][Full Text] [Related]
11. Role of α- and β-adrenergic signaling in phenotypic targeting: significance in benign and malignant urologic disease.
Archer M; Dogra N; Dovey Z; Ganta T; Jang HS; Khusid JA; Lantz A; Mihalopoulos M; Stockert JA; Zahalka A; Björnebo L; Gaglani S; Noh MR; Kaplan SA; Mehrazin R; Badani KK; Wiklund P; Tsao K; Lundon DJ; Mohamed N; Lucien F; Padanilam B; Gupta M; Tewari AK; Kyprianou N
Cell Commun Signal; 2021 Jul; 19(1):78. PubMed ID: 34284799
[TBL] [Abstract][Full Text] [Related]
12. Alpha-1 blocker use increased risk of subsequent renal cell carcinoma: A nationwide population-based study in Taiwan.
Sung SY; Le TTH; Chen JH; Hsieh TF; Hsieh CL
PLoS One; 2020; 15(11):e0242429. PubMed ID: 33211759
[TBL] [Abstract][Full Text] [Related]
13. Repurposing of α1-Adrenoceptor Antagonists: Impact in Renal Cancer.
Mihalopoulos M; Dovey Z; Archer M; Korn TG; Okhawere KE; Nkemdirim W; Funchess H; Rambhia A; Mohamed N; Kaplan SA; Mehrazin R; Lundon D; Tsao CK; Badani KK; Kyprianou N
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32872127
[TBL] [Abstract][Full Text] [Related]
14. Association of finasteride with prostate cancer: A systematic review and meta-analysis.
Wang L; Lei Y; Gao Y; Cui D; Tang Q; Li R; Wang D; Chen Y; Zhang B; Wang H
Medicine (Baltimore); 2020 Apr; 99(15):e19486. PubMed ID: 32282699
[TBL] [Abstract][Full Text] [Related]
15. The role of 5α-reductase inhibitors in gastro-oesophageal cancer risk: A nested case-control study.
Busby J; Karasneh R; Murchie P; McMenamin Ú; Gadalla SM; Camargo MC; Iversen L; Lee AJ; Spence AD; Cardwell CR
Pharmacoepidemiol Drug Saf; 2020 Jan; 29(1):48-56. PubMed ID: 31713940
[TBL] [Abstract][Full Text] [Related]
16. Association between 5α-reductase inhibitors therapy and incidence, cancer-specific mortality, and progression of prostate cancer: evidence from a meta-analysis.
Luo LM; Yang RD; Wang JM; Zhao SK; Liu YZ; Zhu ZG; Xiang Q; Zhao ZG
Asian J Androl; 2020; 22(5):532-538. PubMed ID: 31710001
[TBL] [Abstract][Full Text] [Related]
17. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
[TBL] [Abstract][Full Text] [Related]
18. Influence of the neural microenvironment on prostate cancer.
Coarfa C; Florentin D; Putluri N; Ding Y; Au J; He D; Ragheb A; Frolov A; Michailidis G; Lee M; Kadmon D; Miles B; Smith C; Ittmann M; Rowley D; Sreekumar A; Creighton CJ; Ayala G
Prostate; 2018 Feb; 78(2):128-139. PubMed ID: 29131367
[TBL] [Abstract][Full Text] [Related]
19. Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells.
Ishii K; Matsuoka I; Kajiwara S; Sasaki T; Miki M; Kato M; Kanda H; Arima K; Shiraishi T; Sugimura Y
J Cancer Res Clin Oncol; 2018 Jan; 144(1):89-98. PubMed ID: 29098395
[TBL] [Abstract][Full Text] [Related]
20. The Modulating Effects of Benign Prostate Enlargement Medications on Upgrading Predictors in Patients with Gleason 6 at Biopsy.
Jazayeri SB; Kwon YS; McBride R; Leapman M; Collingwood S; Hobbs A; Samadi DB
Curr Urol; 2017 Jul; 10(2):97-104. PubMed ID: 28785195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
